drugset / Trial / NCT01400607

Neocartilage Implant to Treat Cartilage Lesions of the Knee

NCT01400607 ↗

Phase 3 Terminated 14 enrolled ISTO Technologies, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

ISTO Technologies, Inc. is proposing a clinical study with 225 subjects, to establish the safety and efficacy of the Neocartilage Implant for the treatment of ICRS Grade 3 and 4 articular cartilage lesions of the knee compared to microfracture treatment.

Timeline

Start
2011-07
Primary completion
2020-09
Completion
2020-09

Outcome

Outcome not reported

Stopped (Enrollment): “Poor enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Neocartilage Implant Cell therapy — —